Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/pds.3573 | DOI Listing |
Hypertens Res
January 2025
Department of Cardiology, Yokohama City University School of Medicine, Yokohama, Japan.
Pharmacoeconomics
January 2025
Belgian Health Care Knowledge Centre, Brussels, Belgium.
Background: Forecasting future public pharmaceutical expenditure is a challenge for healthcare payers, particularly owing to the unpredictability of new market introductions and their economic impact. No best-practice forecasting methods have been established so far. The literature distinguishes between the top-down approach, based on historical trends, and the bottom-up approach, using a combination of historical and horizon scanning data.
View Article and Find Full Text PDFClin Drug Investig
January 2025
Department of Medicine, Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Perelman School of Medicine, 423 Guardian Drive, Philadelphia, PA, 19104, USA.
Purpose: The REDUCE-IT randomized trial demonstrated a cardiovascular benefit of icosapent ethyl (IPE) but also raised potential safety signals for atrial fibrillation (AF) and serious bleeding. We aimed to evaluate the real-world safety of IPE versus mixed omega-3 polyunsaturated fatty acid (OM-3) formulations.
Methods: This retrospective active comparator new-user cohort study compared rates of new-onset AF and major bleeding (MB) among adult new users of IPE versus OM-3 in 2020-2024 US Veterans Affairs data.
Nutrients
December 2024
Protein Industries Canada, Centre for Regulatory Research and Innovation, 200-1965 Broad Street, Regina, SK S4P 1Y1, Canada.
Drug Saf
January 2025
Pfizer (Worldwide Medical & Safety), New York, NY, USA.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!